Monte Rosa Therapeutics Q2 2024 GAAP EPS $(0.43) Beats $(0.55) Estimate, Sales $4.695M Beat $1.349M Estimate, Cash Position Of $267.1M Is Expected To Fund Operations Into H1 2027
Portfolio Pulse from Benzinga Newsdesk
Monte Rosa Therapeutics reported a Q2 2024 GAAP EPS of $(0.43), beating the estimate of $(0.55). Sales were $4.695M, surpassing the $1.349M estimate. The company has a cash position of $267.1M, expected to fund operations into H1 2027.
August 08, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monte Rosa Therapeutics reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.43) and sales of $4.695M. The company's strong cash position of $267.1M is expected to fund operations into H1 2027.
The better-than-expected earnings and sales figures, along with a strong cash position, are likely to positively impact Monte Rosa Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100